Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery.

A study of equivalence was performed between two low molecular weight heparins, reviparin-sodium (Clivarin) and enoxaparin (Lovenox) in the prevention of deep vein thrombosis (DVT) after total hip replacement. Nineteen orthopaedic centres participated in the trial. Four hundred and ninety-eight patients were randomized; 247 received reviparin-sodium and 251 enoxaparin; 58 patients were excluded. Each patient received subcutaneous prophylaxis begun 10-12 h pre-operatively and the second injection 10-12 h post-operatively and thereafter every 24 h. In the enoxaparin group 18 DVT were observed (9%); of these 13 (6%) were proximal. In the reviparin-sodium group 21 DVT were observed (10%); 12 (6%) were proximal. The study showed that the efficacy of both LMWHs was equivalent as was the clinical tolerance. There was a slight trend in favour of reviparin-sodium as regards haemoglobin level, and wound haematoma. Anti-factor Xa activity was significantly different despite similar injected doses.

RCT Entities:   Population Interventions Outcomes